Drug Database
Back to search

Poland· PL-100000994

Ifapidin

A ticlopidine product containing ticlopidinum, registered in Poland by Egis Pharmaceuticals Ltd.. The same ATC class is registered in 7 of our 19 countries.

ATC B01AC05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedIfapidinATCB01AC05REGISTER NO.PL-100000994PACKS LISTED5CHECKEDJune 7, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ticlopidinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ticlopidine is registered in 7 of 19 countries.

Countries holding a registration under ATC B01AC05 (ticlopidine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose
Search ticlopidine products by name

Ticlopidine · ATC B01AC05

7 / 19 countries

  • Belgiumprice
  • Franceprice
  • Germany
  • Italyprice
  • Polandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ticlopidine costs, country by country.

Normalised to the WHO defined daily dose (0.5 g), the median price runs from $0.25 in Italy to $1.0 in France — a ×4.0 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ticlopidine · price per daily dose (0.5 g)

USD · FX 28 Sept 2026

  • FR France$1.0
  • ES Spain$0.71
  • IT Italy$0.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ticlopidinum
Manufacturer
Egis Pharmaceuticals Ltd.
Country
Poland (PL)
ATC code
B01AC05
ATC class
Ticlopidine
Defined daily dose
0.5 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
June 7, 2026

Packs & prices · 5

  • gtin
    05909990797110
  • gtin
    05909990797127
  • gtin
    05909990797134
  • gtin
    05909990694846
  • gtin
    05909990694853

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

318 interactions on record for ticlopidine.

Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ticlopidine against other medicinesHow interaction checks work

Ticlopidine · interactions on record

318 records

  • 54 severe
  • 124 moderate
  • 36 minor
  • 104 info

Most severe, free to view

  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • DanaparoidB01AB09severe
  • TinzaparinB01AB10severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ticlopidine in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ticlopidine products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Ticlid, Ticlopidine Teva
  • Germany · Ticlopidin Neuraxpharm, Ticlopidine Ratiopharm
  • Spain · Ticlopidina Cinfa
  • France · Ticlopidine Arrow, Ticlopidine Eg
  • Greece · Ruxicolan Cap
  • Hungary · Aclotin, Ticlid
  • Italy · Chiaro, Clox
  • Luxembourg · Ticlid
  • Portugal · Ticlopidina, Ticlopidina Alter
  • Romania · Ticlodin
  • Slovakia · Ticlopidin Ratiopharm

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/07c75ca1-8a1e-48eb-9057-6d9b68c87fd4
GET /v1/drugs/07c75ca1-8a1e-48eb-9057-6d9b68c87fd4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "250 mg",
  "packaging": "05909990797110 ¦ Rp ¦ 23839\n20 tabl. w blistrze (1 x 20)\n05909990797127 ¦ Rp ¦ 23840\n30 tabl. (2 x 15)\n05909990797134 ¦ Rp ¦ 23841\n60 tabl. w blistrach (3 x 20)\n05909990694846 ¦ Rp ¦ 49632\n60 tabl. w blistrach (6 x 10)\n05909990694853 ¦ Rp ¦ 49633\n20 tabl. w blistrach (2 x 10)",
  "substance": "Ticlopidini hydrochloridum 250 mg",
  "common_name": "Ticlopidinum",
  "pl_product_id": "100000994",
  "pozwolenie_nr": "07971",
  "auth_procedure": "NAR",
  "authorisation_validity": "2023-06-13"
}
API referenceMCP serverPlans

See everything about ticlopidine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console